

AXIM BIOTECH HOLDS ANNUAL BOARD MEETING

NEW YORK – Jan 25, 2017 – AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM), a world leader in cannabinoid research and development, held its second annual board meeting on January 20, 2017 in New York City. AXIM Biotech board members reviewed company milestones in 2016, and discussed clinical trial progress for irritable bowel syndrome (IBS), multiple sclerosis (MS) and psoriasis and eczema (PSO) as well as additional R&D activities for the next 12 months. The meeting also approved budgets needed to carry out the clinical projects and business developments.

Management and advisory board experts considered further proof of concept studies of cannabis based treatment for indications such as nicotine addiction, Restless Leg Syndrome, postherpetic neuralgia, and drug related psychosis. Other items discussed during the board meeting included progress on vertical integration with the manufacturing facility in Almere, Netherland, use of natural versus synthetic cannabinoids and antibacterial preparations with CBG, CBD and halogenated metals.

“AXIM achieved exciting milestone developments in 2016,” said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM Biotech. “We are entering the New Year with a robust clinical pipeline in IBS, MS and PSO and expanded study for additional therapeutic indications. We are fortunate to have research collaboration with leading experts, and will continue to optimize our company structure to execute our business goals. With our patented delivery technology and broad research and product portfolio, AXIM is becoming a leader in the cannabis-based pharmaceutical space.”

###

About AXIM®

AXIM® Biotechnologies, Inc. (OTC: [AXIM](http://www.AXIMBiotech.com)) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. Medical Marijuana, Inc. is a major investor in AXIM. For more information, please visit www.AXIMBiotech.com.

About CanChew® and CanChew Plus®

CanChew® is a unique hemp-derived CBD functional chewing gum that is distinctly different than any other brands of gum on the market. Features listed on the CanChew® website include:

- Non-habit forming
- No prescription needed
- Available in all 50 states

- Great-tasting mint gum has no artificial sweeteners or preservatives
- Non-GMO, gluten free, vegan and kosher

CanChew Plus® is a vastly improved delivery system than the alpha version of CanChew® Gum. It is produced by a leading European functional gum manufacturer.

Featured in Healthy Living Magazine, CanChew® was also recognized by the HealthyLiving Foundation and honored with its Triple Leaf Award.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.

LEGAL DISCLOSURE

AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).

Public Relations Contact:

Andrew Hard

Chief Executive Officer

CMW Media

andrew.hard@cmwmedia.com

P. +1888 829-0070

www.cmwmedia.com

Investor Relations Contact

Shiwei Yin, Grayling

Shiwei.Yin@grayling.com

P. +1646 824-2857

Lucia Domville, Grayling

lucia.domville@grayling.com

P. +1646 284-9416

Corporate Contact Info

North American Address:

18 East 50th Street, 5 Floor

New York, NY 10022

+1 844 294 6246

European Address:

Boelewerf 32, Unit 3

2987 VD Ridderkerk, The Netherlands

+31 10 8209 227